Abstract: An apparatus for heat stress testing canisters having bodies and valve assemblies, including a heating zone, such as an induction coil system for heating the canisters, and a conveying assembly for conveying the longitudinal axis of each canister in a generally vertical orientation relative to the longitudinal axis of the heating zone, the canisters being positioned partially within the heating zone during the heat testing, such that, each canister's body is positioned substantially inside of the heating zone and each canister's valve assembly is positioned substantially or completely outside of the heating zone.

Abstract: A powder dispenser includes: a dispenser housing having including a hopper for holding a powder; an outlet tube; a slider slidably mounted with respect to the dispenser housing between a feed position and a dispense position, the slider including a holding member for receiving powder supplied through a dispensing opening of the hopper in the feed position, the holding member having pores which permit gas passage therethrough but which prevent powder passage therethrough, and a vacuum passage for removing gas trapped by the powder in the holding member, through the holding member wall; an angled bore for supplying a pressurized gas at an angle to the hopper to provide a swirling effect; and a gas supply bore in the dispenser housing for supplying a pressurized gas to the receptacle portion in the dispense position to force the powder from the receptacle portion to the outlet tube.

Abstract: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.

Abstract: Methods are provided for treating proliferative diseases, especially cancers, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an antineoplastic agent and/or radiation therapy.

Abstract: Methods are provided for treating cancer, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an additional Ras signaling pathway inhibitor to induce cancer cell death and tumor regression.

Abstract: The invention provides methods for purifying a virus from impurities in an aqueous medium.

Abstract: Methods are disclosed for treating cancer in a patient in need of such treating comprising administering temozolomide in an amount effective to achieve a clinical response wherein the temozolomide is administered in a microcrystalline suspension.

Abstract: This invention relates to methods for the cultivating cells, and in particular to methods for propagating recombinant viruses for gene therapy.

Abstract: This invention relates to methods for the cultivating cells, and in particular to methods for propagating viruses.

Abstract: Methods are provided for treating proliferative diseases, especially cancers, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an antineoplastic agent and/or radiation therapy.

Abstract: Mammalian proteins and muteins thereof, designated interleukin-4s (IL-4s), are provided which exhibit both B cell growth factor activity and T cell growth factor activity. Compounds of the invention include native human and murine IL-4s, muteins thereof, and nucleic acids which are effectively homologous to disclosed cDNAs, and/or which are capable of coding for mammalian IL-4s and their muteins.

Abstract: Transformed cell lines containing a reporter gene operatively linked to a genetic control element that is responsive to growth factor-stimulated cell proliferation and/or oncogene-mediated neoplastic transformation are provided. Also provided are methods for using such transformed cell lines to screen for growth factor antagonists and/or antineoplastic agents.

Abstract: This invention relates to the use of IL-10, alone or in combination with IL-2 and/or .alpha.-IFN, to treat neoplastic disorders by stimulating cytolytic activity of peripheral blood mononuclear cells with IL-10 alone.

Abstract: Disclosed are compounds of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein: R.sup.3 is alkyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl, cycloalkyl, acyloxymethyl, alkoxy, alkoxymethyl, or alkyl substituted with cycloalkyl;R.sup.4 is H, alkyl, alkenyl, alkoxy, or --OH.Also disclosed are pharmaceutical compositions containing compounds of Formula I, methods for inhibiting tumor necrosis factor-.alpha. and methods for treating septic shock, inflammation, or allergic disease by administering a compound of Formula I.

Abstract: This invention provides a method for inhibiting HIV replication in a patient which comprises administering to a patient infected with HIV a therapeutically effective amount of IL-4.

Abstract: Disclosed are compounds of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, methods for inhibiting tumor necrosis factor-.alpha. and methods for treating septic shock, inflammation, or allergic disease.

Abstract: Mammalian proteins and muteins thereof, designated interleukin-4s (IL-4s), are provided which exhibit both B cell growth factor activity and T cell growth factor activity. Compounds of the invention include native human and murine IL-4s, muteins thereof, and nucleic acids which are effectively homologous to disclosed cDNAs, and/or which are capable of coding for mammalian IL-4s and their muteins.

Abstract: Methods and compositions are provided for treating toxic shock in a mammal. The methods comprise administering to a mammal afflicted with or at high risk for developing toxic shock an effective amount of IL-6.

Abstract: Strains of E. coli are provided which are capable of secreting heterologous recombinant proteins through the outer cell wall and directly into the culture medium. Methods are also provided for making and identifying such strains, and for using them to make heterologous proteins that have high biological activity, without the need for cell disruption.

Abstract: Disclosed are compounds of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein: R.sup.4 is alkenyl, alkoxy, or --OH.Also disclosed are pharmaceutical compositions containing compounds of Formula I, methods for inhibiting tumor necrosis factor-.alpha., and methods for treating septic shock, inflammation, or allergic disease.